Vanguard Group’s TScan Therapeutics TCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.12M | Sell |
2,149,376
-207,370
| -9% | -$301K | ﹤0.01% | 3374 |
|
|
2025
Q1 | $3.25M | Sell |
2,356,746
-25,787
| -1% | -$35.6K | ﹤0.01% | 3325 |
|
|
2024
Q4 | $7.24M | Buy |
2,382,533
+35,639
| +2% | +$108K | ﹤0.01% | 3116 |
|
|
2024
Q3 | $11.7M | Buy |
2,346,894
+213,281
| +10% | +$1.06M | ﹤0.01% | 2876 |
|
|
2024
Q2 | $12.5M | Buy |
2,133,613
+325,461
| +18% | +$1.9M | ﹤0.01% | 2792 |
|
|
2024
Q1 | $14.4M | Buy |
1,808,152
+20,000
| +1% | +$159K | ﹤0.01% | 2764 |
|
|
2023
Q4 | $10.4M | Buy |
1,788,152
+35,558
| +2% | +$207K | ﹤0.01% | 2924 |
|
|
2023
Q3 | $4.49M | Buy |
1,752,594
+393,305
| +29% | +$1.01M | ﹤0.01% | 3296 |
|
|
2023
Q2 | $3.4M | Buy |
1,359,289
+1,062,464
| +358% | +$2.66M | ﹤0.01% | 3471 |
|
|
2023
Q1 | $623K | Buy |
296,825
+30,771
| +12% | +$64.6K | ﹤0.01% | 4058 |
|
|
2022
Q4 | $412K | Buy |
266,054
+8,638
| +3% | +$13.4K | ﹤0.01% | 4154 |
|
|
2022
Q3 | $785K | Buy |
257,416
+31,352
| +14% | +$95.6K | ﹤0.01% | 4073 |
|
|
2022
Q2 | $711K | Sell |
226,064
-865
| -0.4% | -$2.72K | ﹤0.01% | 4192 |
|
|
2022
Q1 | $636K | Sell |
226,929
-11,085
| -5% | -$31.1K | ﹤0.01% | 4334 |
|
|
2021
Q4 | $1.07M | Sell |
238,014
-206,880
| -47% | -$931K | ﹤0.01% | 4251 |
|
|
2021
Q3 | $3.71M | Buy |
+444,894
| New | +$3.71M | ﹤0.01% | 3824 |
|